Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Gelesis (PTCHF) Expects Readout of Pivotal Trial GLOW in H1 2017 Evaluating Gelesis100 in Weight Loss in Overweight and Obese Subjects With and Without Type 2 Diabetes

Source Link:: http://www.gelesis.com/clinical-trials.php

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

PTCHF

100%

Gelesis

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment "Gelesis100, our lead product, is a first-in-class therapeutic which is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. Gelesis100 is administered orally as a capsulated device."

http://www.gelesis.com/

Clinical Data Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

https://clinicaltria...

Additional Relevant Details Update on July 12 2017: Gelesis Announces Last Patient Out in the Pivotal Gelesis100 Weight-Loss Study

http://www.gelesis.c...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 25, 2017

Occurred Source:

http://www.gelesis.com/press-releases/25092017.php

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Pivotal Trial, Glow, Gelesis100, Weight Loss, Overweight, Obese Subjects, Type 2 Diabtetes, Prediabetic Patients